Effectiveness of pentoxifylline on the cross-sectional area of intima media thickness and functions of the common carotid artery in adolescents with type 1 diabetes

Journal of Pediatric Endocrinology and Metabolism

Volumn 24, Issue 11-12, 2011, Pages 945-951

  Atabek, Mehmet Emre ^a   Kurtoglu, Selim ^b   Selver, Beray ^a   Baykara, Murat ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

common carotid artery; early atherosclerosis; pentoxifylline; type 1 diabetes

Indexed keywords

PENTOXIFYLLINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; ARTICLE; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHILD; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC WALL STRESS; DISEASE DURATION; DISEASE MARKER; ECHOGRAPHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTIMA MEDIA THICKNESS; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; THICKNESS;

ADOLESCENT; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; PENTOXIFYLLINE; PLACEBOS; RISK FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 83655172912     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/JPEM.2011.199     Document Type: Article

References (39)

1. Newman WP, Freedman DS, Voors DV, Gard PD, Srinivasan SR, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986;314:138-44. (Pubitemid 16183169)
2. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524. (Pubitemid 17050766)
3. Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 1988;256:205-12.
4. Hiramatsu K, Rosen H, Heinecke JW, Wolfbauer G, Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis 1987;7:55-60. (Pubitemid 17014542)
5. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated modifi cation of low density lipoprotein by arterial smooth muscle cells. J Clin Invest 1986;77:757-61. (Pubitemid 16067946)
6. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6. (Pubitemid 16097810)
7. Tesfamariam B, Cohen RA. Free radicals mediate endothe-lial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263:321-6.
8. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-406. (Pubitemid 17189260)
9. Pujia A, Gnasso A, Iraace C, Colonna A, Mattioli PL. Common carotid arterial wall thickness in NIDDM subjects. Diabetes Care 1994;17:1330-6. (Pubitemid 24324979)
10. Lehmann ED, Riley WA, Clarkson P, Gosling RG. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet 1997;350:114-9.
11. Atabek ME, Kurtoglu S, Demir F, Baykara M. Relation of serum leptin and insulin-like growth factor-1 levels to intima-media thickness and functions of common carotid artery in children and adolescents with type 1 diabetes. Acta Paediatr 2004;93:1052-7. (Pubitemid 39452785)
12. Feldman AM, Mcnamara DM. Reevaluating the role of phospho-diesterase inhibitors in the treatment of cardiovascular disease. Clin Cardiol 2002;25:256-62. (Pubitemid 34568582)
13. Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). A review of its therapeutic effi cacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995;7:480-503.
14. Colgan P, Dormandy JA, Jones PW, Schraibman LG, Shanik DG, et al. Oxpentifylline treatment of venous ulcers of the leg. Br Med J 1990;300:972-5. (Pubitemid 20144222)
15. Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid artherosclerosis. A four-year randomized, controlled clinical study of intima-media thickness measured by ultrasound. Circulation 2001;103:2949-54.
16. Aggoun Y, Bonnet D, Sidi D, Girardet JP, Brucker E, et al. Arterial mechanical changes in children with familial hyper-cholesterolemia. Arterioscler Thromb Vasc Biol 2000;20: 2070-5.
17. Aggoun Y, Sidi D, Levy BI, Lyonnet S, Kachaner J, et al. Mechanical properties of the common carotid artery in Williams syndrome. Heart 2000;84:290-3.
18. Garcia MJ, McNamara PM, Gordon T, Kanell WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 1973;23:105-11.
19. Selzer R, Hodis HN, Kwong-Fu H, Mack WJ, Lee PL, et al. Evaluation of computerized edge tracking for quantifying inti-ma-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 1994;1:1-11. (Pubitemid 24330612)
20. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, et al. Benefi cial effects of colestipol-niacin therapy on the common carotid artery. Two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-8. (Pubitemid 23195428)
21. Byington RP, Furberg CD, Crouse J, Espeland MA, Bond MG. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995;75:455-9.
22. Kodama M, Yamasaki Y, Sakamoto K, Yoshioka R, Matsuhisa M, et al. Antiplatelet drugs attenuate progression of carotid intima media thickness in subjects with type 2 diabetes. Thromb Res 2000;97:239-45. (Pubitemid 30069713)
23. Ahn CW, Lee HC, Park SW, Song YD, Huh KB, et al. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;52:45-53. (Pubitemid 32143687)
24. Chen YM, Wu KD, Tsai TJ, Hsieh BS. Pentoxyfi lline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;31:773-83.
25. Cogny A, Paul JL, Surbled B, Atger V, Lenoble M, et al. Oxidative modifi cation of high-density lipoprotein 3 induced by human polymorphonuclear neutrophils: protective effect of pentoxifyl-line. Eur J Biochem 1999;259:32-9. (Pubitemid 29030815)
26. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 1999;33:458-63. (Pubitemid 29107022)
27. Hansen PR, Holm AM, Qi JH, Ledet T, Rasmussen LM, et al. Pentoxifylline inhibits neointimal formation and stimulates constructive vascular remodeling after arterial injury. J Cardiovasc Pharmacol 1999;34:683-9. (Pubitemid 29491730)
28. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacody-namic and pharmacokinetic properties, and its therapeutic effi-cacy. Drugs 1987;34:50-97. (Pubitemid 17092322)
29. Strohschneider T, Kling D, Betz E. The effect of pentoxyfi lline on endothelial permeability of rabbit carotid anery wall. Eur J Pharmacol 1988;150:287-93.
30. Nenci GG, Gresele P, Agnelli G, Ballatori E. Effect of pentoxyfi l-line on platelet aggregation. Pharmatherapeutica 1981;2:532-8. (Pubitemid 11143946)
31. Dauber IM, Lesnefsky EJ, Ashmore RC, Martel DM, Sheridan FM, et al. Coronary vascular injury due to ischemia-reper-fusion is reduced by pentoxifylline. J Pharmacol Exp Ther 1992;260:1250-6.
32. Belloc F, Jaloustre C, Dumain P, Lacombe F, Lenoble M, et al. Effect of pentoxyfi lline on apoptosis of cultured cells. J Cardiovasc Pharmacol 1995;25:71-4.
33. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995;96:2521-7.
34. Bernard C, Bamier P, Merval R, Esposilo B, Tedgui A. Pentoxyfi lline selectively inhibits tumor necrosis factor synthesis in the arterial wall. J Cardiovasc Pharmacol 1995;25:30-3.
35. Peterson TC. Pentoxyfi lline prevents fi brosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 1993;17:486-93. (Pubitemid 23072825)
36. Basabe JC, Udrisar DP, Knopf CF, Aparico N. The infl uence of pentoxyfylline 1-(5 oxohexyl-3,7-dimetylxanthine (BL 191) on insulin secretion induced by glibenclamide and arginine/glucose in the perfused pancreas. Acta Diabetol Lat 1997;14: 63-72.
37. Striffl er JS, Nadler JL. Lisofylline. A novel anti-infl ammatory agent enhances glucose stimulated insulin secretion in vivo and in vitro studies in prediabetic and normal rats. Metabolism 2004;53:290-6. (Pubitemid 38684687)
38. Noyan T,Yalcinkaya AS, Dülger H, Balaharoglu R. Antioxidant effects of pentoxifylline and melatonin in the alloxane-induced diabetic mice. Turk J Biochem 2004;29:268-72.
39. Yang Z, Chen M, Nadler JL. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol 2005;69:1-5. (Pubitemid 39592866)